Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies

Cindy Ippoliti, Richard Champlin, Najla Bugazia, Donna Przepiorka, Joyce Neumann, Sergio Giralt, Issa Khouri, James Gajewski

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Purpose: Diarrhea associated with acute gastrointestinal (GI) graft- versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT) can result in severe morbidity and mortality. A pilot study was conducted to evaluate the efficacy and toxicity of octreotide in the management of diarrhea in patients with GVHD after allogeneic BMT. Patients and Methods: Twenty-one patients entered the study. Patients received either peripheral- blood stem cells (n = 13) or bone marrow (n = 8). Seven patients had grade 4, 13 grade 3, and one grade 2 GVHD. Intravenous (IV) octreotide 500 μg every 8 hours for 7 days was administered. Octreotide treatment was discontinued if no response was observed after 7 days or for grade 4 toxicity. Results: Fifteen (71%) of 21 treated patients had a complete response within 7 days of the initiation of octreotide; three (14%) had a partial response and three (14%) failed to respond to treatment. Toxicities were minimal; hyperglycemia was seen in four patients and one patient developed a partial ileus. Octreotide was discontinued and the ileus resolved within 48 hours. Conclusion: If initiated early in the course of GI GVHD, octreotide appears to be an effective, well-tolerated agent in reducing severe voluminous diarrhea. Octreotide should be discontinued within 24 hours after the resolution of diarrhea to avoid the development of ileus. Because no additional reduction in the volume of diarrhea occurred after 7 days of therapy, continuation of the drug beyond this time is not cost effective.

Original languageEnglish (US)
Pages (from-to)3350-3354
Number of pages5
JournalJournal of Clinical Oncology
Volume15
Issue number11
StatePublished - Nov 1997
Externally publishedYes

Fingerprint

Octreotide
Graft vs Host Disease
Hematologic Neoplasms
Diarrhea
Ileus
Homologous Transplantation
Bone Marrow Transplantation
Reducing Agents
Hyperglycemia
Bone Marrow
Morbidity
Costs and Cost Analysis
Drug Therapy
Mortality
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ippoliti, C., Champlin, R., Bugazia, N., Przepiorka, D., Neumann, J., Giralt, S., ... Gajewski, J. (1997). Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. Journal of Clinical Oncology, 15(11), 3350-3354.

Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. / Ippoliti, Cindy; Champlin, Richard; Bugazia, Najla; Przepiorka, Donna; Neumann, Joyce; Giralt, Sergio; Khouri, Issa; Gajewski, James.

In: Journal of Clinical Oncology, Vol. 15, No. 11, 11.1997, p. 3350-3354.

Research output: Contribution to journalArticle

Ippoliti, C, Champlin, R, Bugazia, N, Przepiorka, D, Neumann, J, Giralt, S, Khouri, I & Gajewski, J 1997, 'Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies', Journal of Clinical Oncology, vol. 15, no. 11, pp. 3350-3354.
Ippoliti, Cindy ; Champlin, Richard ; Bugazia, Najla ; Przepiorka, Donna ; Neumann, Joyce ; Giralt, Sergio ; Khouri, Issa ; Gajewski, James. / Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies. In: Journal of Clinical Oncology. 1997 ; Vol. 15, No. 11. pp. 3350-3354.
@article{a117b18956b6447cb7df0f2b744086ed,
title = "Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies",
abstract = "Purpose: Diarrhea associated with acute gastrointestinal (GI) graft- versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT) can result in severe morbidity and mortality. A pilot study was conducted to evaluate the efficacy and toxicity of octreotide in the management of diarrhea in patients with GVHD after allogeneic BMT. Patients and Methods: Twenty-one patients entered the study. Patients received either peripheral- blood stem cells (n = 13) or bone marrow (n = 8). Seven patients had grade 4, 13 grade 3, and one grade 2 GVHD. Intravenous (IV) octreotide 500 μg every 8 hours for 7 days was administered. Octreotide treatment was discontinued if no response was observed after 7 days or for grade 4 toxicity. Results: Fifteen (71{\%}) of 21 treated patients had a complete response within 7 days of the initiation of octreotide; three (14{\%}) had a partial response and three (14{\%}) failed to respond to treatment. Toxicities were minimal; hyperglycemia was seen in four patients and one patient developed a partial ileus. Octreotide was discontinued and the ileus resolved within 48 hours. Conclusion: If initiated early in the course of GI GVHD, octreotide appears to be an effective, well-tolerated agent in reducing severe voluminous diarrhea. Octreotide should be discontinued within 24 hours after the resolution of diarrhea to avoid the development of ileus. Because no additional reduction in the volume of diarrhea occurred after 7 days of therapy, continuation of the drug beyond this time is not cost effective.",
author = "Cindy Ippoliti and Richard Champlin and Najla Bugazia and Donna Przepiorka and Joyce Neumann and Sergio Giralt and Issa Khouri and James Gajewski",
year = "1997",
month = "11",
language = "English (US)",
volume = "15",
pages = "3350--3354",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - Use of octreotide in the symptomatic management of diarrhea induced by graft-versus-host disease in patients with hematologic malignancies

AU - Ippoliti, Cindy

AU - Champlin, Richard

AU - Bugazia, Najla

AU - Przepiorka, Donna

AU - Neumann, Joyce

AU - Giralt, Sergio

AU - Khouri, Issa

AU - Gajewski, James

PY - 1997/11

Y1 - 1997/11

N2 - Purpose: Diarrhea associated with acute gastrointestinal (GI) graft- versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT) can result in severe morbidity and mortality. A pilot study was conducted to evaluate the efficacy and toxicity of octreotide in the management of diarrhea in patients with GVHD after allogeneic BMT. Patients and Methods: Twenty-one patients entered the study. Patients received either peripheral- blood stem cells (n = 13) or bone marrow (n = 8). Seven patients had grade 4, 13 grade 3, and one grade 2 GVHD. Intravenous (IV) octreotide 500 μg every 8 hours for 7 days was administered. Octreotide treatment was discontinued if no response was observed after 7 days or for grade 4 toxicity. Results: Fifteen (71%) of 21 treated patients had a complete response within 7 days of the initiation of octreotide; three (14%) had a partial response and three (14%) failed to respond to treatment. Toxicities were minimal; hyperglycemia was seen in four patients and one patient developed a partial ileus. Octreotide was discontinued and the ileus resolved within 48 hours. Conclusion: If initiated early in the course of GI GVHD, octreotide appears to be an effective, well-tolerated agent in reducing severe voluminous diarrhea. Octreotide should be discontinued within 24 hours after the resolution of diarrhea to avoid the development of ileus. Because no additional reduction in the volume of diarrhea occurred after 7 days of therapy, continuation of the drug beyond this time is not cost effective.

AB - Purpose: Diarrhea associated with acute gastrointestinal (GI) graft- versus-host disease (GVHD) after allogeneic bone marrow transplantation (BMT) can result in severe morbidity and mortality. A pilot study was conducted to evaluate the efficacy and toxicity of octreotide in the management of diarrhea in patients with GVHD after allogeneic BMT. Patients and Methods: Twenty-one patients entered the study. Patients received either peripheral- blood stem cells (n = 13) or bone marrow (n = 8). Seven patients had grade 4, 13 grade 3, and one grade 2 GVHD. Intravenous (IV) octreotide 500 μg every 8 hours for 7 days was administered. Octreotide treatment was discontinued if no response was observed after 7 days or for grade 4 toxicity. Results: Fifteen (71%) of 21 treated patients had a complete response within 7 days of the initiation of octreotide; three (14%) had a partial response and three (14%) failed to respond to treatment. Toxicities were minimal; hyperglycemia was seen in four patients and one patient developed a partial ileus. Octreotide was discontinued and the ileus resolved within 48 hours. Conclusion: If initiated early in the course of GI GVHD, octreotide appears to be an effective, well-tolerated agent in reducing severe voluminous diarrhea. Octreotide should be discontinued within 24 hours after the resolution of diarrhea to avoid the development of ileus. Because no additional reduction in the volume of diarrhea occurred after 7 days of therapy, continuation of the drug beyond this time is not cost effective.

UR - http://www.scopus.com/inward/record.url?scp=0030712865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030712865&partnerID=8YFLogxK

M3 - Article

C2 - 9363865

AN - SCOPUS:0030712865

VL - 15

SP - 3350

EP - 3354

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -